Business Context and Reporting Period
Company: Alector, Inc. (Nasdaq: ALEC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Alector is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, focusing on Alzheimer's disease (AD) and Parkinson's disease (PD). The company utilizes its proprietary Alector Brain Carrier (ABC) platform to deliver therapeutics across the blood-brain barrier. Its lead clinical asset is nivisnebart, a progranulin-elevating antibody developed in collaboration with GlaxoSmithKline (GSK).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Collaboration Revenue | $21.0 million | $100.6 million |
| Research & Development Expenses | $123.1 million | $185.9 million |
| General & Administrative Expenses | $54.0 million | $59.6 million |
| Net Loss | $(142.9) million | $(119.0) million |
| Cash, Cash Equivalents, and Marketable Securities | $256.0 million | $413.4 million |
| Accumulated Deficit | $(972.1) million | $(829.1) million |
| Debt Outstanding (Term Loan) | $10.0 million | $10.0 million |
Note: The filing text does not provide a specific "Gross Margin" or "Operating Margin" percentage, as the company is pre-revenue from product sales and incurs significant operating losses.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by approximately 79% to $21.0 million from $100.6 million. This was primarily due to the satisfaction of performance obligations for the AL002 program and the latozinemab FTD-GRN Phase 2 trial in late 2024, resulting in lower revenue recognition in 2025.
- Expense Reduction: Total operating expenses decreased by 28% to $177.1 million. R&D expenses dropped by $62.9 million, driven by the discontinuation of the AL002 program and workforce reductions.
- Program Terminations:
- Latozinemab: In October 2025, the company stopped the open-label extension of the INFRONT-3 Phase 3 trial after the drug failed to meet its clinical co-primary endpoint in frontotemporal dementia (FTD-GRN).
- AL002: In November 2024, the AL002 program was terminated after failing to meet the primary endpoint in the INVOKE-2 Phase 2 trial for early AD. The AbbVie collaboration agreement was subsequently terminated in January 2025.
- Workforce Reductions: The company initiated significant reductions in force (RIF) in 2025. A March 2025 RIF impacted ~13% of the workforce, and an October 2025 RIF impacted ~47% of the workforce. Total restructuring charges for 2025 were approximately $9.6 million ($2.3 million in March and $7.3 million in October).
Guidance, Outlook, and Risks
- Liquidity and Runway: As of December 31, 2025, the company held $256.0 million in cash and marketable securities. Management anticipates this provides a runway at least through 2027, though this estimate is subject to change based on clinical trial progress and capital raising.
- Clinical Pipeline Outlook:
- Nivisnebart: Enrollment in the PROGRESS-AD Phase 2 trial for early AD was completed in April 2025. An independent interim futility analysis is planned for the first half of 2026. Trial completion is expected in 2026.
- Preclinical Pipeline: The company is advancing ABC-enabled candidates including AL137 (anti-amyloid beta for AD), AL050 (GCase enzyme for PD/LBD), and AL064 (tau siRNA for AD). IND submissions are targeted for late 2026 to 2027.
- Key Risks:
- Capital Requirements: The company expects to continue incurring net losses and will require substantial additional financing to fund operations and clinical development.
- Regulatory and Clinical Risk: High failure rates in neurodegenerative drug development; reliance on the success of the nivisnebart Phase 2 trial.
- Collaboration Risk: Dependence on GSK for the development and commercialization of nivisnebart; GSK retains the right to terminate the agreement for convenience.
- Debt Covenants: The company has a $50 million term loan facility (with $10 million drawn) subject to covenants that could restrict operations or trigger default if not met.
Investor Verification Checklist
- Cash Burn Rate: Verify the accuracy of the "through 2027" runway estimate given the recent 47% workforce reduction and the cessation of major revenue streams from the AbbVie and latozinemab programs.
- Nivisnebart Trial Status: Monitor the timeline and results of the interim futility analysis for the PROGRESS-AD Phase 2 trial, scheduled for the first half of 2026.
- Debt Facility Terms: Review the specific covenants in the Hercules Capital loan agreement to understand triggers for default or acceleration of debt.
- Deferred Revenue: Assess the remaining $171.2 million in deferred revenue from the GSK agreement and the assumptions regarding cost-sharing and performance obligations.
- Preclinical Progress: Track the IND-enabling studies for AL137, AL050, and AL064 to ensure the pipeline can sustain the company post-2027 if nivisnebart does not advance to Phase 3.